Pharmaceuticals, Biotechnology and Life Sciences
Sanofi announced on Tuesday that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for lixisenatide.
Meiji Seika Pharma Co., Ltd. announced on Tuesday that the U.S. Food and Drug Administration (FDA) has designated the Company’s lead antibiotic product, ME1100 (arbekacin inhalation solution), as a Qualified Infectious Disease Product (QIDP) for the adjunctive treatment of mechanically ventilated patients with bacterial pneumonia.
FDA has announced that the TF Supplements of Houston is voluntarily recalling the following product to the consumer level: RHINO…
Allergan plc announced on Friday that it has launched a generic version of Janssen’s Invega (paliperidone extended-release tablets) in the…
The U.S. Food and Drug Administration has approved Tresiba (insulin degludec injection) and Ryzodeg 70/30 (insulin degludec/insulin aspart injection) to…
The U. S. Food and Drug Administration approved Taiho Oncology’s Lonsurf for the treatment of patients with metastatic colorectal cancer who…
FDA is warning health care professionals about the risk for dosing errors with the intravenous antibacterial drug Avycaz (ceftazidime and…
The U.S. Food and Drug Administration (FDA) has announced that taking tramadol pain medicine for children under 17 can cause…
Simulations Plus, Inc, a provider of consulting services and software for pharmaceutical discovery and development, announced on September 17 that…
FDA announced on September 15 that Butala Emporium, Inc of Jackson Heights, NY, is voluntarily recalling eleven Ayurvedic (dietary) supplements because the products…
You must be logged in to post a comment.